MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Type 2 Diabetes
Interventions
DRUG

Gliclazide 80mg OD

Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.

DRUG

Sitagliptin 100mg OD

Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.

Trial Locations (1)

EX2 5DW

NIHR Exeter Clinical Research Facility, Royal Devon & Exeter NHS Foundation Trust, Exeter

All Listed Sponsors
collaborator

University of Exeter

OTHER

lead

Royal Devon and Exeter NHS Foundation Trust

OTHER

NCT01847144 - MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes | Biotech Hunter | Biotech Hunter